- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.04. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors | 56 | GlobeNewswire (Europe) | BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today... ► Artikel lesen | |
| 05.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.04. | TransCode Therapeutics reports FY results | 1 | Seeking Alpha | ||
| 03.04. | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports 2023 Results; Provides Business Update | 101 | GlobeNewswire (Europe) | BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported... ► Artikel lesen | |
| 01.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.03. | TransCode Therapeutics appoints Vlock as chief medical officer | 1 | Seeking Alpha | ||
| 28.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer | 122 | GlobeNewswire (Europe) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today... ► Artikel lesen | |
| 11.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment | 197 | GlobeNewswire (Europe) | BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive... ► Artikel lesen | |
| 06.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress | 2 | GlobeNewswire (USA) | ||
| 31.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.01. | Transcode Therapeutics regains compliance with Nasdaq listing rules | 2 | Seeking Alpha | ||
| 31.01. | TransCode Therapeutics, Inc.: Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market | 158 | GlobeNewswire (Europe) | BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics... ► Artikel lesen | |
| 29.01. | Looking Into TransCode Therapeutics' Recent Short Interest | 1 | Benzinga.com | ||
| 29.01. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer | 354 | GlobeNewswire (Europe) | BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced... ► Artikel lesen | |
| 22.01. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Closing of $7.25 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 19.01. | Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session | 2 | Benzinga.com | ||
| 19.01. | TransCode (RNAZ) Down 50% on Issue of New Common Stock | 2 | Zacks | ||
| 19.01. | AEHL, MOR and RNAZ among pre-market losers | 1 | Seeking Alpha | ||
| 18.01. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering | 5 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,940 | -1,65 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
| NOVAVAX | 3,677 | 0,00 % | Novavax mit SONDERMELDUNG: Könnte die Aktie JETZT komplett drehen - Anleger müssen sofort reagieren! | ||
| PALATIN TECHNOLOGIES | 1,612 | +1,38 % | Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive | WASHINGTON (dpa-AFX) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) Monday said it presented positive topline results from the Phase 3 MELODY-1 study of its drug candidate PL9643... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 9,510 | +0,74 % | Pre-market Movers: Macatawa Bank, Ryvyl, WiSA Technologies, Inovio Pharmaceuticals, Mobilicom | STOCKHOLM (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.55 A.M. ET).In the Green Macatawa Bank Corporation (MCBC) is up over 38%... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,800 | -2,70 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
| XOMA | 24,200 | +0,83 % | XOMA Corporation: XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) | XOMA is entitled to a mid-single digit royalty on global OJEMDA sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,673 | +0,30 % | Phio Pharmaceuticals Corp.: Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells | -Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma... ► Artikel lesen | |
| T2 BIOSYSTEMS | 2,815 | -100,00 % | T2 Biosystems, Inc.: T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 8-K, Current Report | ||
| ORAGENICS | 1,150 | +4,55 % | Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards | SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced... ► Artikel lesen | |
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks... ► Artikel lesen | |
| LADRX | 1,289 | -11,47 % | XOMA Corporation: FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx | EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration's (FDA)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 3,510 | -1,40 % | Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results | First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion... ► Artikel lesen | |
| ARAVIVE | 0,033 | -16,67 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.01.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 30.01.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.01.2024ISIN NameCA48214J1093 JUST... ► Artikel lesen | |
| ALTAMIRA THERAPEUTICS | 1,600 | 0,00 % | Altamira Therapeutics Ltd: Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal | Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy... ► Artikel lesen |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,522 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
